We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+57.39%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$570M
AUM Growth
+$120M
Cap. Flow
-$68.6M
Cap. Flow %
-12.04%
Top 10 Hldgs %
59.83%
Holding
55
New
13
Increased
13
Reduced
16
Closed
7

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$15.7M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$12.8M
3
AERI
Aerie Pharmaceuticals
AERI
+$11M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$6.71M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$6.53M

Top Sells

Rank Stock Value
1
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$33.9M
2
TSRO
TESARO, Inc.
TSRO
+$22.1M
3
MDVN
MEDIVATION, INC.
MDVN
+$16.9M
4
RLYP
RELYPSA INC COM
RLYP
+$11.3M
5
GILD icon
Gilead Sciences
GILD
+$9.05M

Sector Composition

Rank Sector Weight
1 Healthcare 83.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
1
Sarepta Therapeutics
SRPT
$1.64B
$84.1M 14.76%
1,369,909
-42,281
-3% -$1.28M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$11.9B
$38.8M 6.81%
419,712
-13,260
-3% -$1.25M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.04B
$35M 6.15%
4,257,347
-81,210
-2% -$687K
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$27.8M 4.88%
277,703
-236,297
-46% -$22.1M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$27.3M 4.79%
3,689,857
-8,808
-0.2% -$59.5K
DERM
6
DELISTED
Dermira, Inc.
DERM
$27.3M 4.78%
805,926
+84,263
+12% +$2.71M
AGEN
7
Agenus
AGEN
$276M
$26.7M 4.68%
189,327
+31,390
+20% +$3.6M
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$4.51B
$25.2M 4.42%
792,499
+462,999
+141% +$15.7M
NBIX icon
9
Neurocrine Biosciences
NBIX
$18.2B
$24.8M 4.36%
490,582
-18,748
-4% -$934K
IMMU
10
DELISTED
Immunomedics Inc
IMMU
$23.9M 4.19%
7,344,177
-1,212,780
-14% -$3.39M
BMY icon
11
Bristol-Myers Squibb
BMY
$129B
$21.6M 3.78%
399,875
-45,464
-10% -$2.92M
GBT
12
DELISTED
Global Blood Therapeutics, Inc.
GBT
$20M 3.52%
869,263
-94,383
-10% -$1.8M
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
$18.9M 3.31%
+500,000
New +$11M
GWPH
14
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$17.7M 3.11%
+133,600
New +$12.8M
VNDA icon
15
Vanda Pharmaceuticals
VNDA
$304M
$13.8M 2.42%
827,693
+118,114
+17% +$1.59M
NDRM
16
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$12.7M 2.23%
686,303
+129,300
+23% +$2.24M
TLGT
17
DELISTED
Teligent, Inc
TLGT
$12.4M 2.18%
163,782
+34,782
+27% +$2.76M
SRNE
18
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$11.9M 2.08%
1,531,273
-124,001
-7% -$835K
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.84M 1.73%
1,488,487
+273,654
+23% +$1.46M
CASC
20
DELISTED
Cascadian Therapeutics, Inc.
CASC
$9.2M 1.61%
935,221
-22,233
-2% -$158K
AKBA icon
21
Akebia Therapeutics
AKBA
$338M
$8.55M 1.5%
944,579
+322,706
+52% +$2.74M
AGIO icon
22
Agios Pharmaceuticals
AGIO
$2.08B
$7.92M 1.39%
+150,000
New +$6.53M
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
$7.64M 1.34%
+141,500
New +$6.71M
VCYT icon
24
Veracyte
VCYT
$4.45B
$6.99M 1.23%
918,556
– –
BCRX icon
25
BioCryst Pharmaceuticals
BCRX
$2.42B
$6.08M 1.07%
+1,379,402
New +$5.51M
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Avoro Capital Advisors held 55 positions worth $570M, up 27% from $450M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors withdrew a net $68.6M in Q3 2016, closing 7 positions and reducing 16 holdings. Its most notable exit was CELATOR PHARMACEUTICALS INC. COMMON STOCK, an estimated $33.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $17.7M.

  • Avoro Capital Advisors's largest Q3 2016 buy was GW Pharmaceuticals Plc American Depositary Shares: 133,600 shares worth $17.7M.
  • Avoro Capital Advisors added most to Acadia Pharmaceuticals in Q3 2016, an estimated $15.7M increase.
  • Avoro Capital Advisors's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $22.1M.
  • Avoro Capital Advisors fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q3 2016, selling an estimated $33.9M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $570M portfolio in Q3 2016.
  • Avoro Capital Advisors opened 13 new positions and closed 7 in Q3 2016.
  • Avoro Capital Advisors's portfolio value rose 27% quarter-over-quarter to $570M.

Based on Avoro Capital Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.